BELANOFF JOSEPH K 4

What Happened Joseph K. Belanoff, CEO of Corcept Therapeutics (CORT), sold 26,198 shares on March 25, 2026 in an open-market transaction. The weighted average sale price was $50.07 per share (range $50.00–$50.32), for total proceeds of approximately $1,311,826. The Form 4 reports this as a sale (transaction code S).

Key Details

• Transaction date: 2026-03-25 (reported on Form 4 filed 2026-03-27).
• Price: weighted average $50.07; actual sale prices ranged $50.00–$50.32 (see footnote F2).
• Shares sold: 26,198; Proceeds ≈ $1,311,826.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: transaction executed pursuant to a Rule 10b5-1 trading plan adopted 11/26/2024 (F1); weighted-average and price range note (F2); Belanoff disclaims beneficial ownership of certain trust-held shares except for pecuniary interest (F3). Power of attorney used to sign the form is on file with the SEC.
• Timeliness: Filed within the required Form 4 window (reported two days after the trade).

Context This was a planned sale under a 10b5-1 trading plan, which typically indicates the transactions were pre-scheduled and not an ad hoc sale based on current company knowledge. Sales under 10b5-1 plans are common and are generally viewed as routine rather than a direct signal of executive sentiment. No options were exercised and no awards or gifts are reported in this filing.